ABBOTT LABORATORIES Operating Cash Flow
ABBOTT LABORATORIES (ABT) reported Operating Cash Flow of $1.31 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-04-29
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $1.31B, a 7.20% decline year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $3.31B, a 15.59% increase year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $2.79B, a 3.03% increase year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was $2.05B, a 4.44% increase year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for fiscal 2025 was $9.57B, a 11.78% increase from fiscal 2024.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for fiscal 2024 was $8.56B, a 17.86% increase from fiscal 2023.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for fiscal 2023 was $7.26B, a 24.21% decline from fiscal 2022.
- ABBOTT LABORATORIES net cash provided by (used in) operating activities for fiscal 2022 was $9.58B, a 9.04% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $1.31B 10-Q · filed 2026-04-29 | $4.63B derived: sum of 2 quarters · filed 2026-04-29 | $7.42B derived: sum of 3 quarters · filed 2026-04-29 | $9.46B derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2025-12-31 | $3.31B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $6.10B derived: sum of 2 quarters · filed 2026-02-20 | $8.15B derived: sum of 3 quarters · filed 2026-02-20 | $9.57B 10-K · filed 2026-02-20 | |||
| 2025-09-30 | $2.79B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $4.83B derived: sum of 2 quarters · filed 2025-10-29 | $6.25B 10-Q · filed 2025-10-29 | $9.12B derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2025-06-30 | $2.05B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $3.46B 10-Q · filed 2025-07-30 | $6.33B derived: sum of 3 quarters · filed 2026-04-29 | $9.04B derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2025-03-31 | $1.42B 10-Q · filed 2026-04-29 | $4.29B derived: sum of 2 quarters · filed 2026-04-29 | $6.99B derived: sum of 3 quarters · filed 2026-04-29 | $8.95B derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2024-12-31 | $2.87B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $5.57B derived: sum of 2 quarters · filed 2026-02-20 | $7.53B derived: sum of 3 quarters · filed 2026-02-20 | $8.56B 10-K · filed 2026-02-20 | |||
| 2024-09-30 | $2.71B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $4.67B derived: sum of 2 quarters · filed 2025-10-29 | $5.69B 10-Q · filed 2025-10-29 | $8.73B derived: sum of 4 quarters · filed 2026-02-20 | |||
| 2024-06-30 | $1.96B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $2.98B 10-Q · filed 2025-07-30 | $6.02B derived: sum of 3 quarters · filed 2026-02-20 | $7.90B derived: sum of 4 quarters · filed 2026-02-20 | |||
| 2024-03-31 | $1.02B 10-Q · filed 2025-04-30 | $4.06B derived: sum of 2 quarters · filed 2026-02-20 | $5.94B derived: sum of 3 quarters · filed 2026-02-20 | $7.14B derived: sum of 4 quarters · filed 2026-02-20 | |||
| 2023-12-31 | $3.04B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $4.92B derived: sum of 2 quarters · filed 2026-02-20 | $6.12B derived: sum of 3 quarters · filed 2026-02-20 | $7.26B 10-K · filed 2026-02-20 | |||
| 2023-09-30 | $1.88B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $3.08B derived: sum of 2 quarters · filed 2024-10-31 | $4.22B 10-Q · filed 2024-10-31 | $6.55B derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-06-30 | $1.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $2.35B 10-Q · filed 2024-07-31 | $4.67B derived: sum of 3 quarters · filed 2025-02-21 | $7.45B derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-03-31 | $1.14B 10-Q · filed 2024-05-02 | $3.47B derived: sum of 2 quarters · filed 2025-02-21 | $6.25B derived: sum of 3 quarters · filed 2025-02-21 | $8.66B derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2022-12-31 | $2.33B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $5.11B derived: sum of 2 quarters · filed 2025-02-21 | $7.52B derived: sum of 3 quarters · filed 2025-02-21 | $9.58B 10-K · filed 2025-02-21 | |||
| 2022-09-30 | $2.78B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $5.19B derived: sum of 2 quarters · filed 2023-11-01 | $7.25B 10-Q · filed 2023-11-01 | $10.32B derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2022-06-30 | $2.41B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.47B 10-Q · filed 2023-08-03 | $7.54B derived: sum of 3 quarters · filed 2024-02-16 | $10.24B derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2022-03-31 | $2.06B 10-Q · filed 2023-05-04 | $5.13B derived: sum of 2 quarters · filed 2024-02-16 | $7.83B derived: sum of 3 quarters · filed 2024-02-16 | $9.96B derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2021-12-31 | $3.07B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $5.77B derived: sum of 2 quarters · filed 2024-02-16 | $7.90B derived: sum of 3 quarters · filed 2024-02-16 | $10.53B 10-K · filed 2024-02-16 | |||
| 2021-09-30 | $2.70B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $4.83B derived: sum of 2 quarters · filed 2022-11-01 | $7.47B 10-Q · filed 2022-11-01 | $11.26B derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | $2.13B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $4.76B 10-Q · filed 2022-08-02 | $8.56B derived: sum of 3 quarters · filed 2023-02-17 | $10.63B derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | $2.64B 10-Q · filed 2022-05-03 | $6.43B derived: sum of 2 quarters · filed 2023-02-17 | $8.50B derived: sum of 3 quarters · filed 2023-02-17 | $9.82B derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | $3.80B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $5.86B derived: sum of 2 quarters · filed 2023-02-17 | $7.19B derived: sum of 3 quarters · filed 2023-02-17 | $7.90B 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $2.07B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $3.39B derived: sum of 2 quarters · filed 2021-11-03 | $4.10B 10-Q · filed 2021-11-03 | $6.52B derived: sum of 4 quarters · filed 2022-02-18 | |||
| 2020-06-30 | $1.32B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.04B 10-Q · filed 2021-08-04 | $4.45B derived: sum of 3 quarters · filed 2022-02-18 | $6.40B derived: sum of 4 quarters · filed 2022-02-18 | |||
| 2020-03-31 | $715.00M 10-Q · filed 2021-05-05 | $3.13B derived: sum of 2 quarters · filed 2022-02-18 | $5.08B derived: sum of 3 quarters · filed 2022-02-18 | $6.14B derived: sum of 4 quarters · filed 2022-02-18 | |||
| 2019-12-31 | $2.42B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.36B derived: sum of 2 quarters · filed 2022-02-18 | $5.42B derived: sum of 3 quarters · filed 2022-02-18 | $6.14B 10-K · filed 2022-02-18 | |||
| 2019-09-30 | $1.95B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $3.01B derived: sum of 2 quarters · filed 2020-11-04 | $3.72B 10-Q · filed 2020-11-04 | $5.49B derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-06-30 | $1.06B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $1.77B 10-Q · filed 2020-07-29 | $3.54B derived: sum of 3 quarters · filed 2021-02-19 | $5.72B derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-03-31 | $712.00M 10-Q · filed 2020-04-29 | $2.48B derived: sum of 2 quarters · filed 2021-02-19 | $4.66B derived: sum of 3 quarters · filed 2021-02-19 | $5.90B derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2018-12-31 | $1.76B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $3.95B derived: sum of 2 quarters · filed 2021-02-19 | $5.19B derived: sum of 3 quarters · filed 2021-02-19 | $6.30B 10-K · filed 2021-02-19 | |||
| 2018-09-30 | $2.18B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.43B derived: sum of 2 quarters · filed 2019-10-31 | $4.54B 10-Q · filed 2019-10-31 | $6.17B derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2018-06-30 | $1.24B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $2.35B 10-Q · filed 2019-07-31 | $3.99B derived: sum of 3 quarters · filed 2020-02-21 | $6.00B derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2018-03-31 | $1.11B 10-Q · filed 2019-05-01 | $2.75B derived: sum of 2 quarters · filed 2020-02-21 | $4.75B derived: sum of 3 quarters · filed 2020-02-21 | $6.10B derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2017-12-31 | $1.64B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $3.65B derived: sum of 2 quarters · filed 2020-02-21 | $5.00B derived: sum of 3 quarters · filed 2020-02-21 | $5.57B 10-K · filed 2020-02-21 | |||
| 2017-09-30 | $2.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $3.36B derived: sum of 2 quarters · filed 2018-10-31 | $3.93B 10-Q · filed 2018-10-31 | $5.10B derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-06-30 | $1.35B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $1.93B 10-Q · filed 2018-08-01 | $3.10B derived: sum of 3 quarters · filed 2019-02-22 | $4.31B derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-03-31 | $574.00M 10-Q · filed 2018-05-02 | $1.74B derived: sum of 2 quarters · filed 2019-02-22 | $2.96B derived: sum of 3 quarters · filed 2019-02-22 | $3.87B derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2016-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $2.39B derived: sum of 2 quarters · filed 2019-02-22 | $3.30B derived: sum of 3 quarters · filed 2019-02-22 | $3.20B 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $1.22B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $2.13B derived: sum of 2 quarters · filed 2017-11-02 | $2.03B 10-Q · filed 2017-11-02 | $2.86B derived: sum of 4 quarters · filed 2018-02-16 | |||
| 2016-06-30 | $909.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $816.00M 10-Q · filed 2017-08-02 | $1.64B derived: sum of 3 quarters · filed 2018-02-16 | $2.84B derived: sum of 4 quarters · filed 2018-02-16 | |||
| 2016-03-31 | -$93.00M 10-Q · filed 2017-05-03 | $735.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.93B derived: sum of 3 quarters · filed 2018-02-16 | $2.87B derived: sum of 4 quarters · filed 2018-02-16 | |||
| 2015-12-31 | $828.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $2.02B derived: sum of 2 quarters · filed 2018-02-16 | $2.96B derived: sum of 3 quarters · filed 2018-02-16 | $2.97B 10-K · filed 2018-02-16 | |||
| 2015-09-30 | $1.20B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $2.14B derived: sum of 2 quarters · filed 2016-11-03 | $2.14B 10-Q · filed 2016-11-03 | $3.38B derived: sum of 4 quarters · filed 2017-02-17 | |||
| 2015-06-30 | $941.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $943.00M 10-Q · filed 2016-08-03 | $2.18B derived: sum of 3 quarters · filed 2017-02-17 | $3.38B derived: sum of 4 quarters · filed 2017-02-17 | |||
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-04 | $1.24B derived: sum of 2 quarters · filed 2017-02-17 | $2.44B derived: sum of 3 quarters · filed 2017-02-17 | $3.34B derived: sum of 4 quarters · filed 2017-02-17 | |||
| 2014-12-31 | $1.24B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $2.44B derived: sum of 2 quarters · filed 2017-02-17 | $3.34B derived: sum of 3 quarters · filed 2017-02-17 | $3.67B 10-K · filed 2017-02-17 | |||
| 2014-09-30 | $1.20B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $2.10B derived: sum of 2 quarters · filed 2015-11-05 | $2.44B 10-Q · filed 2015-11-05 | $4.06B derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2014-06-30 | $900.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $1.24B 10-Q · filed 2015-08-04 | $2.86B derived: sum of 3 quarters · filed 2016-02-19 | $3.38B derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2014-03-31 | $336.00M 10-Q · filed 2015-05-06 | $1.96B derived: sum of 2 quarters · filed 2016-02-19 | $2.48B derived: sum of 3 quarters · filed 2016-02-19 | $3.20B derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $1.63B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $2.15B derived: sum of 2 quarters · filed 2016-02-19 | $2.86B derived: sum of 3 quarters · filed 2016-02-19 | $3.32B 10-K · filed 2016-02-19 | |||
| 2013-09-30 | $522.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.24B derived: sum of 2 quarters · filed 2014-11-06 | $1.70B 10-Q · filed 2014-11-06 | $1.70B 10-Q · filed 2013-11-07 | $3.20B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $717.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $1.18B 10-Q · filed 2014-08-05 | $1.18B 10-Q · filed 2013-08-06 | $2.68B derived: sum of 3 quarters · filed 2015-02-27 | $6.20B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $460.00M 10-Q · filed 2014-05-07 | $460.25M 10-Q · filed 2013-05-08 | $1.96B derived: sum of 2 quarters · filed 2015-02-27 | $5.48B derived: sum of 3 quarters · filed 2015-02-27 | $7.55B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2012-12-31 | $1.50B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $5.02B derived: sum of 2 quarters · filed 2015-02-27 | $7.09B derived: sum of 3 quarters · filed 2015-02-27 | $9.31B 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $3.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $5.59B derived: sum of 2 quarters · filed 2013-11-07 | $7.81B 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $2.07B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $4.29B 10-Q · filed 2013-08-06 | |||||
| 2012-03-31 | $2.22B 10-Q · filed 2013-05-08 | ||||||
| 2011-12-31 | $8.97B 10-K · filed 2014-02-21 | ||||||
| 2011-06-30 | $2.50B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-04 | $4.51B 10-Q · filed 2011-08-04 | |||||
| 2011-03-31 | $2.01B 10-Q · filed 2011-05-06 | ||||||
| 2010-09-30 | $2.55B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $4.90B derived: sum of 2 quarters · filed 2011-08-04 | $6.42B 10-Q · filed 2010-11-05 | ||||
| 2010-06-30 | $2.35B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-04 | $3.87B 10-Q · filed 2011-08-04 | |||||
| 2010-03-31 | $1.52B 10-Q · filed 2011-05-06 | ||||||
| 2009-09-30 | $3.03B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $4.74B derived: sum of 2 quarters · filed 2010-11-05 | $5.44B 10-Q · filed 2010-11-05 | ||||
| 2009-06-30 | $1.71B derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-05 | $2.41B 10-Q · filed 2010-08-05 | |||||
| 2009-03-31 | $698.72M 10-Q · filed 2010-05-04 | ||||||
| 2008-09-30 | $2.70B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | $5.76B 10-Q · filed 2009-11-06 | |||||
| 2008-06-30 | $3.06B 10-Q · filed 2009-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |